FDA Approves New Treatments for Depression, Menopause, and Mental Health Conditions
Table of Contents
New therapies targeting major depressive disorder, vasomotor symptoms, and schizophrenia receive FDA clearance, alongside a novel probiotic supplement and a generic injectable antipsychotic.
The Food and Drug Administration recently approved a series of new pharmaceutical and health products, signaling advancements in the treatment of diverse conditions ranging from mental health to menopausal symptoms. These approvals include a novel adjunct therapy for depression, a first-of-its-kind treatment for menopause-related hot flashes, a new probiotic supplement, and a generic long-acting injectable antipsychotic.
Lumateperone Receives Expanded Approval for Major Depressive Disorder
Lumateperone (Caplyta; Johnson & Johnson) has been granted FDA approval as an adjunct therapy to antidepressants for adults struggling with major depressive disorder. Previously approved for schizophrenia and depressive episodes associated with bipolar I or II disorder, the drug is an oral, once-daily atypical antipsychotic.
According to a company release, results from two phase 3 global, double-blind, placebo-controlled trials demonstrated the efficacy and safety of lumateperone in this new indication. The studies showed statistically significant and clinically meaningful improvements in depression symptoms when added to existing antidepressant treatment. Investigators found that a 42 mg dose of lumateperone significantly improved both depression symptoms and disease severity while maintaining a favorable tolerability profile.
Bayer’s Elinzanetant Offers New Hope for Menopause Relief
In a significant development for women experiencing menopause, the FDA has approved elinzanetant (Lynkuet; Bayer) – the first dual NK1 and NK3 receptor antagonist specifically designed to treat moderate to severe vasomotor symptoms (VMS). These symptoms, commonly known as hot flashes and night sweats, can significantly impact quality of life.
Elinzanetant works by acting within the brain’s thermoregulatory center to restore temperature balance disrupted during menopause. The approval was supported by data from three phase 3 clinical trials – OASIS-1 (NCT05042362), OASIS-2 (NCT05099159), and OASIS-3 (NCT05030584) – which collectively demonstrated significant and sustained reductions in both the frequency and severity of VMS, as well as improvements in sleep and overall menopause-related quality of life.
O Positiv Health Launches URO Metabolism + Probiotic
Addressing the growing consumer interest in gut health and metabolic support, O Positiv Health has introduced URO Metabolism + Probiotic, a daily supplement aimed at boosting energy, curbing cravings, reducing bloating, and supporting healthy weight management in women.
The supplement combines clinically informed metabolic support with a targeted probiotic blend. Key ingredients include chromium picolinate for appetite regulation and blood glucose control, vitamin B12 for energy metabolism, and a blend of caffeine and green coffee extract to enhance metabolism and focus. The probiotic component features Bifidobacterium lactis IDCC 4301, Akkermansia, and Lactobacillus gasseri, chosen for their roles in digestive comfort, gut health, and weight management.
Lupin Introduces Generic Risperidone Injectable Suspension
Lupin has launched a generic version of risperidone for extended-release injectable suspension, available in 25-mg, 37.5-mg, and 50-mg single-dose vials. The product offers a more affordable alternative to Risperdal Consta, a long-acting injection used in the treatment of schizophrenia and as maintenance therapy for bipolar I disorder.
This launch marks Lupin’s first commercial application of PrecisionSphere, a long-acting injectable technology developed by its Nanomi subsidiary. The company has been granted 180 days of competitive generic therapy exclusivity for this product. According to a company statement, the formulation can be used alone or in conjunction with lithium or valproate.
These recent approvals represent continued progress in addressing a range of health needs, offering new and potentially improved treatment options for patients and consumers alike.
